Technology
Health
Biotechnology

Aduro Biotech

$3.20
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.06 (1.91%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Aduro Biotech and other stocks, options, ETFs, and crypto commission-free!

About

Aduro Biotech, Inc. Common Stock, also called Aduro Biotech, is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Read More Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA.

Employees
152
Headquarters
Berkeley, California
Founded
2000
Market Cap
250.74M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
599.37K
High Today
$3.22
Low Today
$3.04
Open Price
$3.14
Volume
156.38K
52 Week High
$9.00
52 Week Low
$2.34

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
2015 IPO
US
North America

News

Yahoo FinanceMay 15

Aduro Biotech to Host Investor Event Featuring ADU-S100 Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting

BERKELEY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host and webcast an investor event on Monday, June 3, 2019 at 6:30 am CDT in Chicago, IL. Guest speaker, Dr. Funda Meric-Bernstam of MD Anderson Ca...

25
Simply Wall StMay 8

Does Aduro BioTech, Inc.’s (NASDAQ:ADRO) CEO Pay Matter?

114
NasdaqMay 8

Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates

Aduro BioTech, Inc. ADRO incurred first-quarter 2019 loss of 29 cents per share, wider than the Zacks Consensus Estimate of a loss of 17 cents as well as the year-ago loss of 28 cents. Revenues came in at $3.9 million, down 40.9% year over year due to an absence of a $3- million milestone payment received from Merck MRK in 2018. The top line also missed the Zacks Consensus Estimate of $8.08 million. Shares of Aduro have soared 67.1% so far this year, outperforming the industry's increase of 6%. Quarter i...

194

Earnings

-$0.36
-$0.30
-$0.25
-$0.19
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 1, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.